REFERENCES
1. Yackey K, Stanley R. Off-Label
Prescribing in Children Remains High: A Call for Prioritized Research.Pediatrics. 2019;144(4):e20191571.
2. Aronson JK, Ferner RE. Unlicensed
and off‐label uses of medicines: definitions and clarification of
terminology. British Journal of Clinical Pharmacology.2017;83(12):2615-2625.
3. Costa H, Costa TX, Martins RR, et
al. Use of off-label and unlicensed medicines in neonatal intensive
care. PLoS One. 2018;13(9):e0204427.
4. de Souza AS, dos Santos DB, Rey LC,
et al. Off-label use and harmful potential of drugs in a NICU in Brazil:
A descriptive study. BMC Pediatrics. 2016;16(1):1-10.
5. Flint RB, van Beek F, Andriessen P,
et al. Large differences in neonatal drug use between NICUs are common
practice: time for consensus? Br J Clin Pharmacol.2018;84(6):1313-1323.
6. Cuzzolin L, Agostino R. Off-label
and unlicensed drug treatments in Neonatal Intensive Care Units: an
Italian multicentre study. Eur J Clin Pharmacol.2016;72(1):117-123.
7. Barr J, Brenner-Zada G, Heiman E,
et al. Unlicensed and off-label medication use in a neonatal intensive
care unit: a prospective study. Am J Perinatol. 2002;19(2):67-72.
8. O’Donnell CP, Stone RJ, Morley CJ.
Unlicensed and off-label drug use in an Australian neonatal intensive
care unit. Pediatrics. 2002;110(5):e52.
9. Allegaert K, Mian P, van den Anker
JN. Developmental Pharmacokinetics in Neonates: Maturational Changes and
Beyond. Curr Pharm Des. 2017;23(38):5769-5778.
10. Pratico AD, Longo L, Mansueto S,
et al. Off-Label Use of Drugs and Adverse Drug Reactions in Pediatric
Units: A Prospective, Multicenter Study. Curr Drug Saf.2018;13(3):200-207.
11. Chinese Journal of Pediatrics.
Chinese Expert Consensus of Pediatric Off-Label Drug Use. China J
Pediatr. 2016;54(2):101-103.
12. Zhang L, Li Y, Huang L, et al.
Off -label drug use in pediatric wards of west china second university
hospital in 2010: a cross sectional study. Chin J Evid-Based Med.2012;12(03):267-273.
13. Shi Q, Wang X, Wang W, et al.
Analysis of off-label drug use in neonatal department. China
Pharmacy. 2014;25(14):1265-1267.
14. Liu M, Zhang S, Song Y. Analysis
of off-label drug use of inpatients of neonatology department.Chinese Pharmaceutical Affairs. 2018;32(03):404-411.
15. Zhang L, Li Y, Liu Y, et al.
Pediatric off-label drug use in China: risk factors and management
strategies. Journal of Evidence-Based Medicine. 2013;6(1):4-18.
16. Palmaro A, Bissuel R, Renaud N,
et al. Off-label prescribing in pediatric outpatients.Pediatrics. 2015;135(1):49-58.
17. t Jong GW, Vulto AG, de Hoog M,
et al. A survey of the use of off-label and unlicensed drugs in a Dutch
children’s hospital. Pediatrics. 2001;108(5):1089-1093.
18. Lass J, Kaar R, Jogi K, et al.
Drug utilisation pattern and off-label use of medicines in Estonian
neonatal units. Eur J Clin Pharmacol. 2011;67(12):1263-1271.
19. Emmerich J, Dumarcet N, Lorence
A. France’s new framework for regulating off-label drug use. N
Engl J Med. 2012;367(14):1279-1281.
20. Frattarelli DA, Galinkin JL,
Green TP, et al. Off-label use of drugs in children. Pediatrics.2014;133(3):563-567.
21. Zhang L, Li Y, Zeng L, et al.
Evidence-based evaluation on off-label drug use policies in 15
countries. Chinese Journal of Evidence-Based Medicine.2012;12(04):426-435.
22. Mudur G. Indian Medical
Association wants off-label prescribing. British Medical Journal.2004;328(7446):974.
23. Mei M, Xu H, Wang L, et al.
Current practice and awareness of pediatric off-label drug use in
Shanghai, China -a questionnaire-based study. BMC Pediatrics.2019;19(1):281-288.
24. Neubert A, Lukas K, Leis T, et
al. Drug utilisation on a preterm and neonatal intensive care unit in
Germany: a prospective, cohort-based analysis. Eur J Clin
Pharmacol. 2010;66(1):87-95.
25. Giacoia GP, Birenbaum DL, Sachs
HC, et al. The newborn drug development initiative. Pediatrics.2006;117(3 Pt 2):S1-8.
26. Sachs AN, Avant D, Lee CS, et al.
Pediatric information in drug product labeling. Jama.2012;307(18):1914-1915.
27. Laughon MM, Avant D, Tripathi N,
et al. Drug labeling and exposure in neonates. JAMA Pediatr.2014;168(2):130-136.
28. Allegaert K, Smits A, van den
Anker JN. Drug evaluation studies in neonates: how to overcome the
current limitations. Expert Rev Clin Pharmacol.2018;11(4):387-396.
29. Versporten A, Sharland M,
Bielicki J, et al. The antibiotic resistance and prescribing in European
Children project: a neonatal and pediatric antimicrobial web-based point
prevalence survey in 73 hospitals worldwide. Pediatr Infect Dis
J. 2013;32(6):e242-253.
30. Camacho-Gonzalez A, Spearman PW,
Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis.Pediatr Clin North Am. 2013;60(2):367-389.
31. McWilliam SJ, Antoine DJ, Smyth
RL, et al. Aminoglycoside-induced nephrotoxicity in children.Pediatr Nephrol. 2017;32(11):2015-2025.
32. Conroy S, McIntyre J, Choonara I.
Unlicensed and off label drug use in neonates. Arch Dis Child
Fetal Neonatal Ed. 1999;80(2):F142-144; discussion F144-145
33. Clark RH, Bloom BT, Spitzer AR,
et al. Reported medication use in the neonatal intensive care unit: data
from a large national data set. Pediatrics.2006;117(6):1979-1987.
34. Dell’Aera M, Gasbarro AR,
Padovano M, et al. Unlicensed and off-label use of medicines at a
neonatology clinic in Italy. Pharm World Sci. 2007;29(4):361-367.
35. van den Anker J, Allegaert K.
Rational Use of Antibiotics in Neonates: Still in Search of Tailored
Tools. Healthcare (Basel). 2019;7(1):28-40.